ABT-263-loaded B-Z-PON

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Advanced Research Projects Agency and 5 more

Animals1

Outcomes

RPE function

upin mice1

1 study

ABT-263-loaded B-Z-PON improves RPE function in mice.
“resulted in the selective ablation of senescent cells, restoration of RPE function, and improved visual outcomes.”
Animalsin aged and senescence-induced retinal degeneration modelsretinal pigment epithelium
Bst2-targeted senotherapy restores visual function by eliminating senescent retinal cells
Nature communications18 Mar 2026

Visual function

upin mice1

1 study

ABT-263-loaded B-Z-PON improves visual function in mice.
“resulted in the selective ablation of senescent cells, restoration of RPE function, and improved visual outcomes.”
Animalsin aged and senescence-induced retinal degeneration modelsretina
Bst2-targeted senotherapy restores visual function by eliminating senescent retinal cells
Nature communications18 Mar 2026

Senescent cells

downin mice1

1 study

ABT-263-loaded B-Z-PON decreases senescent cells in mice.
“In vivo administration of ABT-263-loaded B-Z-PON in aged and senescence-induced retinal degeneration models resulted in the selective ablation of senescent cells”
Animalsin aged and senescence-induced retinal degeneration modelsretina
Bst2-targeted senotherapy restores visual function by eliminating senescent retinal cells
Nature communications18 Mar 2026

Latest

1 in 12 months

Nature Communications19 Mar

Bst2-targeted senotherapy restores visual function by eliminating senescent retinal cells

Experiments in miceEye

Paper

ABT-263-loaded B-Z-PON

Outcomes

Latest

Bst2-targeted senotherapy restores visual function by eliminating senescent retinal cells

Related